DR6 protein was also proposed to serve as a diagnostic or prognostic biomarker for some specific tumors, such as gliomas, adult sarcoma, and ovarian cancer since its level was obviously elevated in the serum or tumor tissues of the cancer patients (Sasaroli et al., 2011; Yang et al., 2012). Here, TNFRSF21 is linked to glioma.